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ABSTRACT
Biosimilars have been developed for several 
biologic therapeutic agents, including 
erythropoiesis-stimulating agents (ESAs). 
However, biosimilars cannot be assumed to be 
completely identical to the reference product, 
nor can two different biosimilars of the same 
reference product be considered equivalent. 
Accordingly, standards for approving biosimilars 
are distinct from those for generic versions of 
conventional pharmaceuticals. 
By late 2007, two biosimilar epoetins (HX575 
and SB309) had been approved by the European 
Medicines Agency (EMA), following a series 
of pharmacokinetic and pharmacodynamic 
equivalence studies, as well as phase 3 clinical 
comparability evaluations. Additionally, 
the results of a limited number of post-
authorization interventional or observational 
studies and quality comparisons were published 
subsequently on both products.
The reported differences in glycosylation 
profiles between these epoetin biosimilars and 
their reference product, as well as the lack 
of long-term safety and efficacy evaluation, 
could indicate a need to develop a more 
comprehensive analysis of the available data, 
and to evaluate the post-authorization real-life 
data, in order to gain a better understanding 
of any potential implications of molecular 
structural or formulation differences on long-
term safety and effectiveness.
Switching between an original reference ESA 
and a biosimilar (and possibly also switching 
between biosimilar versions of the same 
product) should be regarded as a change in 
clinical management. Clinicians need to be fully 
involved in such decisions. Prescribing by brand 
name will prevent unintentional substitution 
by pharmacists and allow for effective 
pharmacovigilance, in accordance with recent 
EU directives. In this review, the authors have 
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biosimilars must conduct comparability studies 
to substantiate the similar nature of the new 
similar biological agent and its chosen authorized 
reference agent; EMA guidance states that the 
active substance of a similar biological medicinal 
product must be similar, in molecular and 
biological terms, to the active substance of the 
reference medicinal product. Whether a specific 
product is considered similar is determined on 
a case-by-case basis. However, any differences 
between the similar biological agent and the 
reference agent also have to be justified by 
appropriate studies on a case-by-case basis. 
It is known that recombinant epoetins 
made in different cell lines can differ in their 
carbohydrate structure, and this may affect their 
pharmacokinetics (PK) and potency [2, 6, 7]. 
In recognition of the potential impact of such 
differences, the World Health Organization 
(WHO) recommended assigning a different 
Greek letter identifier to distinguish epoetin 
drug substances differing in carbohydrate 
structure [8]. However, the interpretation of 
this rule with respect to biosimilar products has 
been voluntary on the part of the sponsor, with 
resulting inconsistency in its interpretation for 
biosimilar products approved in Europe. 
Additionally, because the cells used to produce 
recombinant biologics usually release several 
isoforms, and since clinical efficacy depends on 
maintaining a specific 3-dimensional molecular 
structure, small differences or changes in any of 
analyzed most of the published information on 
the two epoetin biosimilars, HX575 and SB309, 
to highlight the points that healthcare providers 
may need to consider when assessing an epoetin 
biosimilar.
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INTRODUCTION
Since approval of the first recombinant human 
insulin in 1982, biologics have accounted 
for an increasing proportion of treatments 
approved by the European Medicines Agency 
(EMA) [1–2]. Recently, the patents for 
many biologics have expired [3], allowing 
manufacturers to produce alternatives, 
commonly referred to as “biosimilars” [3–4]. 
Table 1 lists the biosimilar erythropoietins 
currently licensed in Europe [5]. The introduction 
of biosimilar products is welcomed by the clinical 
community, as they may help to reduce drug 
expenditure and allow more patients access to 
high-cost therapies. Due to the complexity of 
manufacturing for biologic medicines, distinct 
regulatory pathways have been implemented.
The challenges for manufacturers and 
regulators posed by biosimilars are not 
straightforward, in contrast to the situation with 
conventional generic drugs. Manufacturers of 
Table 1  Biosimilar epoetins currently licensed in Europe [5] 
Molecule INN Brand name
HX575 Epoetin alfa Abseamed® (Medice Arzneimittel Putter, Iserlohn, Germany)
Binocrit® (Sandoz GmbH, Kundl, Austria)
Epoetin alfa Hexal® (Hexal Biotech, Holkirchen, Germany)
SB309 Epoetin zeta Retacrit® (Hospira, Lake Forest, IL, USA)
Silapro® (Stada, Bad Vilbel, Germany)
INN  international nonproprietary name
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Products for Human Use (CHMP) had issued 
guidance covering the general requirements for 
clinical studies of biosimilars and individual 
requirements for each protein [12]. This reflects 
a long-standing recognition among European 
Union (EU) regulators that the generics 
approach is not appropriate for biologics. 
Within the EU, in addition to demonstrating 
biophysical similarity, it is obligatory that 
manufacturers provide sufficient nonclinical (in 
vitro studies and in vivo PK, pharmacodynamic 
[PD], and toxicological studies) and clinical data 
to demonstrate clinical similarity/therapeutic 
equivalence to the reference agent [10]. The 
approval of biosimilar epoetins for treatment 
of renal anemia previously required at least two 
confirmatory efficacy studies in patients with 
CKD, including one correction phase study using 
subcutaneous (SC) administration in epoetin-
naïve patients and one maintenance study using 
intravenous (IV) administration in patients 
previously treated with epoetins. Revised 
guidelines released in 2010 allowed an alternative 
approach of showing comparable efficacy for 
one route of administration (reasonably, the SC 
route, to provide the mandatory comparative 
immunogenicity data) in a comparative clinical 
trial and providing comparative single dose and 
multiple dose PK/PD bridging data for the other 
route of administration [13].
If the biosimilar epoetin sponsor seeks a label 
with multiple indications, it is possible that 
approval may be granted based on a single efficacy 
study in a single appropriate indication [10]. The 
rationale for this is that the mechanism of action 
of epoetin is the same for all currently approved 
indications and there is only one known epoetin 
receptor. Thus, demonstrating efficacy and safety 
in one indication, for example, in renal anemia, 
may allow the manufacturer to extrapolate 
the results to the originators’ other indications 
that use the same route of administration [13]. 
the manufacturing steps for recombinants could 
subsequently change that structure [4]. The 
increase in the number of pure red cell aplasia 
(PRCA) cases among patients with chronic kidney 
disease (CKD) who were given a reformulation of 
an epoetin product exemplifies the potential for 
seemingly small changes in biopharmaceutical 
production to induce rare but potentially serious 
adverse events [9]. It also underscores the 
importance of long-term follow-up and effective 
pharmacovigilance [10–11]. 
Almost 5 years after the introduction of 
the first biosimilar epoetin in Europe, this 
article focuses on reviewing the registrational 
clinical studies and key post-marketing studies 
conducted in support of the currently available 
epoetin biosimilars, HX575 and SB309. Rather 
than providing a critique of HX575 and SB309, 
the article aims to discuss present experience 
with epoetin biosimilars, based on currently 
published data, and the points that could be 
considered by regulatory bodies, pharmacists, 
and clinicians.
METHODS
A systematic search was not conducted. An 
initial search using the terms “biosimilars,” 
“epoetins,” “epoetin alfa,” “epoetin zeta,” 
“epoetin theta,” “Binocrit,” and “Retacrit” was 
conducted on PubMed, and additional material 
was retrieved from the websites of regulatory 
authorities (EMA, WHO, etc.). Further references 
were identified from the reference lists of the 
publications that were retrieved.
REGULATORY APPROVAL OF 
BIOSIMILARS
As opposed to the situation with generic drugs, 
where manufacturers are required to conduct 
only PK studies, the Committee for Medicinal 
Adv Ther (2013)  30(1):28–40. 31
This situation applies to all biosimilar 
applications, not just that for epoetin. For 
example, the chemotherapy-induced anemia 
indication for all epoetin biosimilars was granted 
by extrapolation of data [13].
Design of Therapeutic Equivalence Studies 
for Biosimilar Epoetins 
A trial that aims to show therapeutic equivalence 
of epoetins requires the pre-specification of a 
clinically accepted margin for the differences 
between treated groups. A careful assessment 
and a clinical rationale are, therefore, needed 
to define the accepted margin appropriately. 
The CHMP recommends that each therapeutic 
equivalence study for biosimilar epoetins has 
two pre-specified co-primary endpoints: change 
in hemoglobin and change in average dose [12]. 
Thus, a biosimilar can be approved based 
on therapeutic equivalence on both primary 
endpoints, as shown by two-sided confidence 
intervals (CIs) for between-group differences 
being within pre-specified margins. However, 
these recommendations have evolved following 
the advent of biosimilars and some equivalence 
studies preceded their introduction.
CLINICAL DATA AND ISSUES FOR 
SPECIFIC BIOSIMILAR EPOETINS
HX575
Substance HX575 (Rentschler Biotechnologie, 
Laupheim, Germany) was approved by the 
EMA in late 2007 and has been marketed since 
then as Binocrit® by Sandoz (Sandoz GmbH, 
Kundl, Austria), as epoetin alfa Hexal® by 
Hexal Biotech (Holkirchen, Germany; another 
Novartis subsidiary) and as Abseamad® by 
Medice Arzneimittel Putter (Iserlohn, Germany; 
a Sandoz licensing partner) [14].
HX575 has the same amino acid sequence as 
the reference product (Eprex®, Erypo®, Janssen-
Cilag, New York, NY, USA), but has a greater 
number of phosphorylated high mannose-6-
phosphate (M6P) glycans, and lower levels of 
N-glycolylneuraminic acid and diacetylated 
neuraminic acids [15–16]. Despite the WHO 
recommendations to assign a different Greek 
suffix for each recombinant epoetin, HX575 is 
using the same international nonproprietary 
name (INN) of epoetin alfa [8].
Clinical Pharmacology
The pivotal IV PK/PD study compared HX575 
and epoetin alfa (both 100 IU/kg) three-times 
weekly for 4 weeks. The study enrolled 80 healthy 
men and the primary endpoint for PK was area 
under the curve (AUC) for epoetin concentration, 
while the primary endpoint for PD was the area 
under the effect curve for hemoglobin (AUECHb). 
The two products could be considered 
pharmacokinetically bioequivalent if the 90% CIs 
of HX575 epoetin AUC were within 80–125% of 
the reference product, and pharmacodynamically 
bioequivalent if the 90% CI for the AUECHb ratio 
was within 96.8–103.2% [17].
Based on the AUECHb ratio and 90% CI (99.9% 
[98.5–101.2%]), the hematopoietic profiles of 
HX575 and epoetin alfa were similar. The two 
products were deemed equivalent. However, 
after only a single IV dose, some PK differences 
were noted, as demonstrated by the 18% 
lower AUC0-12h after HX575 versus epoetin alfa 
administration; geometric mean (geometric mean 
coefficient of variation) 8,098 mIU/mL*h (44.5%) 
after HX575 versus 9,903 mIU/mL*h (33.3%) after 
epoetin alfa. Although HX575 was considered 
pharmacokinetically equivalent to epoetin alfa 
following multiple IV administrations, at steady 
state, the AUC0-36h was approximately 10% lower 
after HX575 than after epoetin alfa; geometric 
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mean (geometric mean coefficient of variation) 
8,153 mIU/mL*h (25.4%) for HX575 versus 
9,036 mIU/mL*h (21.1%) for epoetin alfa [17].
The 10% reduction in exposure, as assessed 
by changes in HX575 AUC observed in this 
study, together with the more complicated 
manufacturing process of biopharmaceuticals, 
further supports EMA guidance that PK profile 
alone is insufficient to support the similar efficacy 
and safety of two biotechnology-derived medicinal 
products [12]. In clinical practice, a reduction 
in exposure could translate into a change in 
clinical response due to significant fluctuation in 
erythropoietin therapeutic levels [17]. Therefore, 
clinicians may need to monitor hemoglobin levels 
and modify the dose of HX575 after switching 
patients who are stable on epoetin alfa. 
Another PK study compared SC HX575 and 
epoetin beta, finding that the AUC of HX575 
was also approximately 10% lower than the 
comparator, whereas the maximum serum 
concentration (Cmax) differed by only 3%. However, 
these findings have limited relevance [18], 
since epoetin alfa was not used as a reference [15].
Safety and Efficacy
One maintenance study in clinically stable adult 
dialysis patients was conducted with HX575. 
A total of 478 patients received HX575 (n = 314) 
or epoetin alfa (n = 164) for 28 weeks, followed 
by HX575 until week 56. HX575 and epoetin alfa 
were considered to be clinically equivalent if the 
95% CI of the hemoglobin difference was within 
the pre-specified equivalence limit (0.5 g/dL) [19]. 
Based on this criterion, HX575 was deemed 
equivalent to epoetin alfa. The hemoglobin 
difference was 0.084 g/dL (95% CI −0.170 to 
0.338). The mean baseline epoetin dosages were 
7,054 IU/week in the HX575 group and 6,623 
IU/week for epoetin alfa. The least square mean 
absolute dose changes were –469.9 (±148.8) and 
–642.2 (±181.5) IU/week, respectively. Thus, 
from baseline (weeks −2 to 0) to evaluation 
(weeks 25–28), patients receiving epoetin alfa 
experienced dose reductions of 7.4%, while 
patients receiving HX575 had dose reductions of 
3.8%. As no pre-specified equivalence margin for 
this relative dose change was given, it is difficult 
to determine whether these differences are 
potentially clinically meaningful or indicate that 
a greater dose of HX575 is required for similar 
clinical response. Moreover, factors such as batch-
to-batch variations cannot be excluded [19]. 
In this maintenance IV study, no significant 
differences in patterns of adverse events were 
noted and no patient showed signs of PRCA [19].
As part of post-authorization risk management 
plans required by the EMA, an open-label, 
prospective single-arm study was conducted on 
more than 1,500 patients with CKD [20]. HX575 
was given via the IV route, mainly to assess its 
long-term safety profile, while efficacy was a 
secondary outcome. Safety was assessed in the full 
patient population and was reported to be in line 
with expectations, with no patient developing 
PRCA. The efficacy results for hemoglobin 
and epoetin dosing showed maintenance of 
hemoglobin within levels of 11.2–11.3 g/dL 
following conversion from other erythropoiesis-
stimulating agents (ESAs). Analysis of the data on 
hemoglobin and ESA dosing was restricted to the 
per-protocol dataset, which excluded almost 33% 
of the patient population [20].
HX575 is currently indicated only for IV use 
in hemodialysis patients, reflecting the lack of a 
successfully completed comparator trial with the 
SC route. An attempted label extension study 
for this route of administration was terminated 
due to unexpected safety findings (PRCA), the 
potential relevance of which is discussed later in 
this review [21, 22]. 
While these results suggest that HX575 is 
well tolerated and effective, some issues remain 
Adv Ther (2013)  30(1):28–40. 33
unresolved, particularly whether differences in 
glycosylation and epoetin exposure are clinically 
meaningful [3, 7, 9, 21]. One further trial has also 
raised the prospect of a difference in potency, 
depending on the manufacturing production 
site [23]. This study compared HX575 and 
other registered epoetin alfa products over 
4 weeks of treatment. Healthy subjects (n = 
268) were randomized to receive HX575 or 
Epogen® (Amgen Inc, Thousand Oaks, CA, USA). 
Both agents were found to be bioequivalent, 
though HX575 exposure was shown to be 
approximately 10% lower [23]. The study then 
compared HX575TT, which was manufactured 
at a different site from HX575, with Eprex/
Erypo. The epoetins produced comparable PD 
responses; however, the AUC of HX575TT was 
15% higher than that of HX575, suggesting that 
the potency of HX575 may differ depending 
on the production site [23]. Additionally, the 
manufacturers did not prospectively define the 
PK acceptance range in registration trials and the 
AUC after IV treatment was outside the post-hoc 
range [3]. 
SB309
SB309 (Norbitec, Uetersen, Germany) was 
the second epoetin biosimilar to receive EMA 
approval. With the INN of epoetin zeta, it 
has been traded subsequently as Silapo® by 
Stada (Bad Vilbel, Germany) and as Retacrit®
by Hospira (Lake Forest, IL, USA). The protein 
backbone of SB309 is similar to that of epoetin 
alfa, but it contains a slightly higher amount 
of glycoforms without an O-glycan chain. The 
amounts of undesired N-glycolyl and acetylated 
forms of neuraminic acid are higher in epoetin 
alfa than SB309 [16, 24]. There are, however, no 
known clinical consequences of the presence of 
the variants of neuraminic acid at the levels that 
are present in these products [25].
Clinical Pharmacology
Several clinical trials have studied the PK 
and PD of SB309. The first trial compared 
the bioavailability of SB309 and epoetin alfa 
following a single IV dose (n = 21). The 90% 
CI for Cmax was within the acceptance ranges, 
which were defined post-hoc. The 90% CI for 
AUC fell within these acceptance ranges after 
the application of a correction factor allowing 
for differences in protein content. After applying 
the correction factor, the bioavailability of SB309 
was reported to be 0.93 (0.89, 0.97) [24, 26].  
A second trial examined the bioavailability 
of SC versus IV SB309 and compared the PK 
characteristics of SB309 and epoetin alfa after a 
single SC dose in healthy volunteers (n = 48). 
The study results (primary analysis) suggested 
sub-availability of SB309 versus epoetin alfa [27]. 
The 90% CIs for AUC and Cmax were within 
the post-hoc defined ranges, after applying 
the correction factor [24]. Some authors have 
suggested that the lower bioavailability of SB309 
in both studies reflected the greater protein 
content of epoetin alfa [24, 26, 27].
Safety and Efficacy
The safety and efficacy of SB309 have been 
studied in three clinical trials. Two of these 
investigated IV use, either for correction of 
anemia or as maintenance therapy [28, 29]. In the 
correction phase study, patients were randomized 
to treatment with SB309 (n = 305) or epoetin alfa 
(n = 304) for 24 weeks [28]. The mean (± standard 
deviation [SD]) hemoglobin level over the final 
4 weeks of treatment was 11.61±1.27 g/dL for the 
patients treated with SB309 versus 11.63±1.37 g/dL 
for patients treated with epoetin alpha, which 
was within the pre-defined equivalence range. 
The mean (±SD) weekly dosage of epoetin per kg 
body weight during the last 4 weeks of treatment 
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was approximately 10% higher with SB309 
compared with epoetin alfa (182.20±118.11 vs. 
166.14±109.85 IU/kg/week) [28]. A correction 
factor was used to reanalyze original data with 
respect to dosage, in order to correct for the higher 
protein content noted in epoetin alfa compared 
to SB309 [24]. Despite this, the correction phase 
study failed to meet its pre-specified criteria for 
equivalence of ±14 IU/kg/week (95% CI –23.5 to 
17.48 IU/kg/week). However, the 95% CI were 
within a modified post-hoc acceptance range of 
±45 IU/kg/week [24, 28].
The  maintenance  s tudy  enrol led 
313 hemodialysis patients with renal anemia who 
had received epoetin for ≥3 months [29]. Patients 
were randomized to receive one epoetin product 
for 12 weeks and then the other for an additional 
12 weeks in a crossover design study. Each 
epoetin was given IV three times per week over a 
12-week treatment period [29]. Mean hemoglobin 
levels were 11.35 g/dL (range: 8.96–14.22 g/dL) 
and 11.54 g/dL (range: 8.7–13.84 g/dL) 
for SB309 and epoetin alfa, respectively. The 
95% CIs of the intraindividual differences in 
hemoglobin levels (0.09–0.28 g/dL) were within 
the pre-defined ranges [29]. Switching from 
epoetin alfa to SB309 increased the dose required 
by approximately 10–15% and transiently 
decreased the hemoglobin level by approximately 
5%. Switching from SB309 to epoetin alfa reduced 
the dose required by around 10% and increased 
hemoglobin levels by approximately 10% [24, 29]. 
As in the correction phase study, a correction 
factor was introduced to correct for differences in 
protein content of the two ESAs being compared. 
In the maintenance phase study, this led to a 
widening of the revised 95% CI for dosage of 
3.086–13.917 IU/kg/week. Again, the 95% CIs 
were within the modified acceptance range of 
±45 IU/kg/week [24, 29].
One weakness of this study was that the 
12-week treatment period for each epoetin 
would not have allowed enough time for dose 
titration of hemoglobin values back to baseline 
levels. In a crossover study of this design, longer 
treatment periods would have allowed a better 
comparison of the dose required to maintain 
consistent hemoglobin levels. In addition, 
mean hemoglobin levels and epoetin doses 
were calculated over the whole 12-week period 
instead of waiting until any overlapping effects 
of the ESAs were over. 
The long-term safety of IV SB309 during 
maintenance of target hemoglobin in patients 
with anemia receiving chronic hemodialysis 
has been reported [30]. Combined outcomes 
from 745 patients who completed double-
blind treatment during the two earlier efficacy 
trials were analyzed [28, 29]. Patients received 
SB309 for 56 weeks or 108 weeks to maintain 
individually determined, stable hemoglobin 
values between 10.5–12.5 g/dL with constant 
epoetin dosages. Although 213 patients 
withdrew during the first 56 weeks due to adverse 
events, noncompliance, and other factors, 
SB309 maintained hemoglobin levels within the 
target range at a constant dose. Infections and 
infestations (34% of patients treated with SB309) 
emerged as the most common adverse event. 
Two patients expressed anti-epoetin antibodies; 
however, these were present at screening for the 
preceding trial. Approximately 5% of adverse 
events were considered to be related to the 
study treatment. Almost 100% of patients and 
investigators reported tolerability as excellent or 
good, and most adverse events that were possibly 
related to study treatment were consistent with 
those previously reported with ESAs [30].
A further post-hoc analysis of the two 
24-week, randomized, double-blind correction 
and maintenance studies and the 56-week, open-
label, follow-on study reported above evaluated 
the impact of switching hemodialysis patients 
with CKD between epoetin alfa and SB309 on 
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hemoglobin concentration, epoetin dose, and 
safety [28–31]. 
In the maintenance study, 118 patients 
switched from epoetin alfa to SB309 and 121 
switched from SB309 to epoetin alfa; 104 of 
the 121 patients switched back to SB309. Only 
101 patients completed 12 weeks of follow-up 
treatment without apparent major protocol 
deviations. In the correction study, 249 of 268 
patients switched from epoetin alfa to SB309. 
A total of 242 patients completed 12 weeks 
of follow-on treatment without any apparent 
major protocol deviations. Therapies were 
considered equivalent if the 95% CI of the 
mean intraindividual difference in hemoglobin 
concentration before and after the switch 
remained within the pre-specified equivalence 
limits (±1.0 g/dL) [31].
Hemoglobin levels were considered to be 
maintained if the mean level remained within the 
target range (10.5–12.5 g/dL) 8–12 weeks after the 
switch. Mean differences in hemoglobin and 95% 
CIs following the switch remained within pre-
specified equivalence ±1.0 g/dL limits (10.94±0.84 
g/dL for SB309 vs. 11.02±0.94 g/dL for epoetin alfa 
at 12 weeks); however, this range is wider than 
the 0.50–0.75 g/dL ranges used in other epoetin 
comparative studies. The 95% CIs of the mean 
difference in weekly epoetin dose stayed within 
modified equivalence margins. The incidence and 
nature of treatment-emergent and serious adverse 
events was similar among all groups and was 
unaffected by the ESA switch. It was reported that 
no patient developed anti-epoetin antibodies or 
PRCA during the study [31].
The safety and efficacy of SC SB309 and 
epoetin alfa have also been compared in 
patients with renal anemia undergoing chronic 
hemodialysis [32]. In a maintenance study, 
patients received SB309 (n = 232) or epoetin alfa 
(n = 230) for 28 weeks after an open run-in period 
of 12–16 weeks, during which time the dose of 
epoetin was adjusted. Mean (±SD) hemoglobin 
concentrations during the last 4 weeks were 
10.94±0.84 g/dL with SB309 and 11.02±0.94 g/dL 
with epoetin alfa, while the mean (±SD) weekly 
epoetin doses were 97.0±94.3 and 86.0±78.0 
IU/kg/week, respectively. The 95% CI of the 
difference in mean hemoglobin level (−0.28 
to 0.12 g/dL) and dose (−8.06 to 29.96 IU/kg/
week) was within the 45 IU/kg/week equivalence 
range [32]. In this study it was reported that 
there were no differences in tolerability between 
treatment groups, and no patient developed 
anti-epoetin antibodies or clinical signs of PRCA. 
Nevertheless, the dropout rate was relatively 
high, with 72 patients (15.6% of the randomized 
population [n = 462]) withdrawing [32].
IMMUNOGENICITY RISK 
Immunogenicity is one of the most important 
potential adverse drug reactions that might 
be associated with the use of biologics, with 
PRCA offering a striking, albeit rare, example 
of a serious adverse event [10, 33]. Many cases 
of immunogenicity are asymptomatic; for 
example, patients taking recombinant human 
insulin develop antibodies without clinical 
consequences [33]. Nevertheless, the production 
of antibodies against an endogenous protein 
may undermine therapeutic efficacy, induce 
autoimmunity to endogenous molecules, 
or produce systemic immune reactions [2]. 
Immunogenicity can arise from minor changes 
in manufacturing and may emerge early or only 
after long-term exposure [33, 34], underscoring 
the need for effective pharmacovigilance.
None of the pre-registration IV epoetin 
biosimilar studies reported the presence of 
neutralizing anti-epoetin antibodies, or any 
signs and symptoms consistent with immune-
mediated PRCA, although it should be noted 
that small numbers of subjects were enrolled 
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into the studies and the duration of treatment 
was relatively short. 
The recent early cessat ion of  the 
Study to Evaluate the Efficacy, Safety and 
Immunogenicity of Subcutaneous HX575 
in the Treatment of Anemia Associated with 
Chronic Kidney Disease (SWEEP) could also 
reflect the importance of understanding 
and evaluating the potential immunogenic 
implications of any minor differences in 
manufacturing or packaging of biologics. 
SWEEP randomized 337 pre-dialysis patients 
who had not previously taken ESAs to receive 
either HX575 or Erypo [21]. Two patients in 
the HX575 arm developed neutralizing anti-
epoetin antibodies; bone marrow biopsy 
confirmed PRCA in one patient, while the 
other patient died from myocardial infarction 
before a biopsy could be conducted [21]. The 
probability of this observation should be put 
into context of the background level of PRCA 
for other ESAs approved for the SC route. 
Published pharmacovigilance data suggest 
the background rate of PRCA for epoetin beta, 
darbepoetin alfa, and epoetin alfa prior to 
the formulation change was approximately 
1 in 100,000 patient-years [35, 36]. Prevalence 
of PRCA during previously reported clusters 
approached 5/10,000 patient-years for Eprex 
and 1/2,608 patient-years for certain ESAs in 
Thailand [37–38]. In this context, the SWEEP 
trial would not have been expected to detect any 
incidence of neutralizing antibodies and this 
finding highlights the importance of clinical 
evaluation, even if events are expected to be 
rare and the study should not have sufficient 
power for detection. A recently published root 
cause analysis suggested that contamination 
by tungsten during manufacturing of the 
syringes used for primary packaging, leading 
to protein denaturation and aggregation of 
HX575 batches, might have been responsible 
for the higher immunogenicity reported in 
this study [22]. HX575 has not received EMA 
authorization for a label revision permitting the 
SC route of administration in CKD patients not 
on dialysis, because of this unexpected finding.
In conclusion, the immunogenicity risk 
associated with biosimilar epoetins cannot be 
excluded. Notwithstanding the unexpected 
finding of anti-erythropoietin-neutralizing 
antibodies in the SWEEP study for HX575 [21, 22], 
only long-term clinical experience involving 
a relatively large number of patients, in 
conjunction with careful pharmacovigilance, 
will provide more robust information.
DISCUSSION 
Biologics are likely to remain among the most 
clinically successful therapeutic agents. It has 
been almost 5 years since biosimilar epoetins 
first became available. The evidence summarized 
here supports the view expressed by others 
that prescribers should be aware of the clinical 
considerations associated with switching between 
reference products and biosimilars [2, 10, 11, 34]. 
Certainly, similar PK profiles alone do not support 
the assumption of similar efficacy and safety of 
two biotechnology-derived medicinal products. 
While it was reported that several studies 
met the bioequivalence endpoints required 
by the EMA between a biosimilar epoetin 
and the reference agent, many of these trials 
had limitations in terms of study design and 
execution. Equivalence margins need to be 
better defined and adhered to when designing 
clinical studies. Currently, while target ranges for 
hemoglobin levels are routinely set and adhered 
to in the studies seeking to prove biosimilarity 
between ESAs, epoetin dose ranges are either 
not being set, are being set inappropriately, 
or are not being adhered to. For example, in 
registration trials, the dosing acceptance range 
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for SB309 was pre-defined but not met and a 
post-hoc correction factor in the maintenance 
study was required to bring the parameters 
within the range [29]. Despite this, the dosage 
of SB309 was approximately 10% higher than 
that for epoetin alfa. 
The studies reviewed in this paper highlight 
other clinical considerations. For example, the 
finding that the AUC for HX575TT was 15% higher 
than that of HX575 [23] may suggest that potency 
depends on the production site. Additionally, 
the epoetin products may have some differences 
in formulation and glycosylation patterns, and 
potential effects on potency cannot be excluded. 
The unexpected rate of neutralizing antibodies 
and the PRCA reported in the SWEEP study with 
SC HX575 [21] emphasize the potential 
uncertainties and need for further understanding 
of the potential differences in immunogenic 
profiles between biosimilars and originators. 
While it has been suggested that tungsten-related 
aggregation of HX575 batches could have been 
responsible for differences in the immunologic 
responses seen in SWEEP, as tungsten has also been 
found in other ESAs, this potential association 
may need to be investigated further [22]. 
Studies of currently licensed biosimilar 
epoetins showed a varying degree of 
glycosylation compared with the reference drug. 
For example, HX575 (Binocrit) has a higher M6P 
content (40%) compared with the reference 
epoetin. Glycosylation plays several roles in the 
biological properties and effects of therapeutic 
proteins, potentially impacting protein folding 
and trafficking, ligand recognition and binding, 
biological activity, stability, pharmacokinetics, 
and immunogenicity. Thus, when evaluating 
a biosimilar epoetin, it may be essential to 
assess the impact of differences in carbohydrate 
content on all of these properties. Additionally, 
the potential impact of batch-to-batch variations 
in both biosimilar epoetins and reference 
products may need to be considered. Since 
small changes in the manufacturing process 
could have an unexpected impact on the 
clinical outcome of follow-on biosimilars, tests 
for consistency in manufacturing processes 
are critical in assessment of any biological 
product. Moreover, as biological products are 
very sensitive to environmental factors, such as 
light and temperature, stability testing should be 
conducted using study designs that are able to 
account for these environmental factors.
The execution of long-term post-marketing 
safety studies and appropriate risk management 
plans will be crucial in generating a better 
understanding of the long-term safety profiles 
of recently approved biosimilar epoetins. 
Some points for clinicians to consider are 
summarized in Table 2. A switch between the 
Table 2  Points for the clinician to consider
•	 Pre-registration clinical trials, study design, sample size
•	 Study population and how representative it is of the clinical population
•	 Study duration, statistical methodology
•	 Difference between the trial and reference drug (biologic activity, route of administration, median dosage, and endpoint
•	 The need to establish local protocols/care bundles to avoid inadvertent drug interchange, or switching administration 
route (IV vs. SC)
•	 Safety, adverse events, potential for immunogenicity
•	 Post-marketing data, clinical experience, adverse event reporting
IV  intravenous, SC subcutaneous
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reference product and the biosimilar may be 
considered “as a change in clinical management,” 
as advocated by Mellstedt and colleagues [4]. 
Arguably, the same applies to switching between 
biosimilar versions of the same reference product. 
If clinicians wish to ensure that a given patient 
receives a specific biologic or biosimilar, they should 
prescribe by brand name to prevent unintentional 
substitution by pharmacists and allow for effective 
pharmacovigilance. This approach has been highly 
recommended in guidelines and legislation released 
in different EU countries, advocating the avoidance 
of automatic substitution [10]. 
In recognition of the need for special 
requirements for effective pharmacovigilance 
for biologics, new pharmacovigilance legislation 
came into effect across the EU in July 2012 [39]. 
This legislation requires that for all adverse 
drug reaction reports, all appropriate measures 
should be taken to identify the brand name and 
batch number of the product concerned. Recent 
EMA guidance has reaffirmed the fundamental 
differences between biosimilar and generic 
medicines, and acknowledged the importance 
of the patient and physician in prescribing/
switching decisions, recommending that 
“for questions related to switching from one 
biological medicine to another, patients should 
speak to their doctor and pharmacist” [40]. 
CONCLUSION
Although considered therapeutically equivalent 
by the EMA, the registration studies for HX575 
and SB309 reviewed here suggest that differences 
in their PK and dosing properties exist. The CHMP 
strongly recommends that each confirmatory 
study for biosimilar epoetins has two co-primary 
endpoints – change in hemoglobin and change in 
average dose – and that a biosimilar is approved 
based on therapeutic equivalence on both primary 
endpoints, assessed by CIs for between-group 
differences that lie within pre-specified margins. 
Such co-primary endpoints appear to have not 
been included when some biosimilar studies 
were undertaken. As differences do exist between 
biosimilars, both in terms of their means of 
manufacturing and glycosylation profiles, long-
term safety and tolerability should continue to be 
monitored. Automatic substitution of biological 
medicines is not encouraged and clinicians 
should be fully involved when a switch between 
originator products and biosimilars is considered. 
Additionally, appropriate pharmacovigilance 
measures should be put in place to ensure that 
adverse events are attributed to the responsible 
biological medicine.
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